Elizabeth McNany, MD
Family Medicine · Fayetteville, NYNPI 1346494655
Payments from drug & device makers
Across 85 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$216
- Otsuka America Pharmaceutical, Inc.$164
- Novo Nordisk$160
- AbbVie$148
- Pfizer$130
- Lundbeck LLC$94
- plus $562 from 17 others
What the payments were for
- Food & beverage$1,475100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 12 | $216 |
| Otsuka America Pharmaceutical, Inc. | 8 | $164 |
| Novo Nordisk | 10 | $160 |
| AbbVie | 10 | $148 |
| Pfizer | 7 | $130 |
| Lundbeck LLC | 5 | $94 |
| AstraZeneca(2 entities) | 4 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $60 |
| Exact Sciences | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Merck | 2 | $42 |
| GSK | 3 | $42 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $42 |
| Boehringer Ingelheim | 2 | $31 |
| IBSA Pharma Inc. | 2 | $28 |
| Madrigal Pharmaceuticals | 1 | $27 |
| Johnson & Johnson | 1 | $26 |
| Shield Therapeutics Inc | 1 | $24 |
| Ferring Pharmaceuticals Inc. | 1 | $22 |
| Gilead | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Axonics, Inc. | 1 | $16 |
| Amgen | 1 | $15 |
How this compares
$1,475 in reported general payments places this provider in the 70th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 78 | $98,140 |
| JardianceEmpagliflozin | 51 | $59,597 |
| EliquisApixaban | 50 | $45,589 |
| MounjaroTirzepatide | 27 | $36,899 |
| TrulicityDulaglutide | 26 | $32,953 |
| XareltoRivaroxaban | 33 | $26,926 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 29 | $21,753 |
| JanuviaSitagliptin Phosphate | 15 | $20,301 |
| Cinacalcet Hcl | 12 | $16,579 |
| Incruse ElliptaUmeclidinium Bromide | 27 | $8,496 |
| MyrbetriqMirabegron | 12 | $7,995 |
| Levothyroxine Sodium | 255 | $3,867 |
| Duloxetine Hcl | 75 | $3,191 |
| Atorvastatin Calcium | 251 | $2,538 |
| Novolog FlexpenInsulin Aspart | 11 | $2,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $160 | $98,14078 claims |
| Lilly USA, LLCMounjaro, Trulicity | $216 | $69,85153 claims |
| Boehringer IngelheimJardiance | $31 | $59,59751 claims |
| PfizerEliquis | $130 | $45,58950 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $42 | $30,24856 claims |
| Johnson & JohnsonXarelto | $26 | $26,92633 claims |
| MerckJanuvia | $42 | $20,30115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,321 family medicine providers in New York.
Other family medicine in Fayetteville
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.